Halo Pharmaceuticals, acquired by Cambrex in 2018 for $425 million and later sold to SK Capital Partners in 2023, is a drug product CDMO specializing in oral solids, liquids, creams, sterile and non-sterile ointments, complex formulations, pediatric indications, and controlled substances. The company operates 430,000 square feet of GMP-compliant manufacturing space across Whippany, New Jersey and Montreal, Quebec, serving over 85 clients.
oral solid dose, liquids and semi-solids, topicals, controlled substances, complex formulations, sterile manufacturing
7 sites worldwide
Involvement in 13 clinical trials
No reviews available yet.
No documents available.